# Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

> **NCT00238121** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 56 (actual)

## Conditions studied

- Recurrent Uterine Sarcoma
- Stage III Uterine Sarcoma
- Stage IV Uterine Sarcoma
- Uterine Carcinosarcoma

## Interventions

- **DRUG:** sorafenib tosylate

## Key facts

- **NCT ID:** NCT00238121
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2015-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00238121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00238121, "Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00238121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*